Novartis France to cut a further 80 r&d jobs
The French arm of Novartis is planning to close two of its r&d centres in France with a loss of 80 jobs.
The French arm of Novartis is planning to close two of its r&d centres in France with a loss of 80 jobs.
The sites to close are bio-analysis at Reuil-Malmaison in Hauts-de-Seine and pharmaceutical development in Orleans.
According to Novartis France, the parent company has decided to transfer these activities to major international sites in the US, Switzerland and emerging economies, based on the need to centralise, simplify and rationalise costs.
Novartis France makes it clear that these job cuts are separate from those involved in the French component of the "Forward" cost-cutting project.